You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百济神州(06160.HK)替雷利珠单抗注射液获药监局批准用於治疗尿路上皮癌
阿思达克 04-14 08:52
百济神州(06160.HK)公布,於2020年4月10日宣布抗PD-1抗体百泽安(通用名:替雷利珠单抗注射液)获得国家药品监督管理局批准用於治疗接受含铂化疗失败包括新辅助或辅助化疗12个月内进展的局部晚期或转移性PD-L1高表达的尿路上皮癌患者。

公司於4月13日宣布,替雷利珠单抗注射液联合培美曲塞及铂类化疗药物用於治疗一线非鳞状非小细胞肺癌患者的3期临床试验在计划的中期分析中,经独立评审委员会评估达到主要终点,即与仅用培美曲塞和铂类药物相比,无进展生存期取得了统计显着性的提高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account